Trump announces 100% chip tariff as Apple ups U.S. investment
PMGC Holdings manages and grows its portfolio through strategic acquisitions, investments, and development in various industries. Its subsidiaries include Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. The company, which boasts an impressive gross profit margin of 71.15% and revenue growth of 112.17% in the last twelve months, remains focused on exploring opportunities across multiple sectors to enhance growth and value. For deeper insights into PMGC Holdings' financial health and growth prospects, including 12 additional exclusive ProTips, visit InvestingPro.
PMGC Holdings manages and grows its portfolio through strategic acquisitions, investments, and development in various industries. Its subsidiaries include Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. The company, which boasts an impressive gross profit margin of 71.15% and revenue growth of 112.17% in the last twelve months, remains focused on exploring opportunities across multiple sectors to enhance growth and value. For deeper insights into PMGC Holdings' financial health and growth prospects, including 12 additional exclusive ProTips, visit InvestingPro.
This press release does not represent an offer to sell or a solicitation of an offer to buy the securities mentioned. The sale of these securities will not proceed in any jurisdiction where such offer, solicitation, or sale is unlawful prior to registration or qualification under the securities laws of that jurisdiction.
PMGC Holdings manages and grows its portfolio through strategic acquisitions, investments, and development in various industries. Its subsidiaries include Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. The company, which boasts an impressive gross profit margin of 71.15% and revenue growth of 112.17% in the last twelve months, remains focused on exploring opportunities across multiple sectors to enhance growth and value. For deeper insights into PMGC Holdings' financial health and growth prospects, including 12 additional exclusive ProTips, visit InvestingPro.
The information is based on a press release statement, and the forward-looking statements within are not guarantees of future performance. These statements reflect current beliefs and expectations about future business plans, strategies, and anticipated trends. PMGC Holdings advises that actual results may differ from those projected and suggests investors review the company's SEC filings for a more comprehensive understanding of risks and uncertainties.
In other recent news, PMGC Holdings Inc. has achieved full compliance with Nasdaq's minimum bid price requirement, a significant accomplishment following a warning of non-compliance received in November 2024. The company has also reported the rebranding of two of its wholly-owned subsidiaries, Elevai Research Inc. and Elevai Biosciences, Inc., now known as PMGC Research Inc. and Northstrive Biosciences Inc., respectively. These developments are part of PMGC Holdings' broader rebranding strategy.
PMGC Holdings has also seen leadership changes at its subsidiaries, with Graydon Bensler assuming the CEO role at PMGC Research Inc., and Braeden Lichti stepping in as Chairman. The company has completed its reincorporation from Delaware to Nevada, and HTL International, LLC has been appointed as the new independent registered public accounting firm.
In terms of acquisitions, Carmell Corporation has purchased assets from PMGC Holdings' subsidiary, Elevai Skincare Inc., for approximately $1.1 million. This acquisition includes Elevai's skincare and haircare business, which has a trailing twelve-month revenue of about $2.5 million.
Furthermore, PMGC Holdings' subsidiary, Elevai Biosciences, is preparing for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for its novel obesity treatment, EL-22. The company has also signed a Master Services Agreement with KCRN Research, Inc. to support the development of EL-22. These are the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.